About Novelix Pharmaceuticals Limited
Data last updated: 22 December 2025
Novelix Pharmaceuticals Limited is a public limited company based in Himayathnagar, Telangana, India. It specialises in pharmaceutical retail and distribution, a part of the broader pharmaceuticals sector. Incorporated on 13 December 1994, the company has been in operation for over 32 years.
Registered with ROC Hyderabad under CIN L67120TG1994PLC018956. Listed on BSE: 536565.
Capital: an authorised share capital of ₹30 Cr and a paid-up capital of ₹16.14 Cr. Formerly known as Trimurthi Drugs & Pharmaceuticals Limited and Trimurthi Limited. It is led by directors including Jivamohan Divakar Valluri and Gnana Prakash Gattu.
Last AGM: 27 September 2024. Financial statements filed for year ended 31 March 2024. Office: Himayathnagar, Telangana.
As per the financials filed for FY 2024, the company reported a revenue of ₹4.53 Cr, a growth of 136% compared to the previous year.
Its group structure includes 1 subsidiary.
The company is associated with 1 brand - Trimurthi Drugs And Pharmaceuticals. As per MCA filings, the company has open charges of ₹85 Lakh on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website trimurthidrugs.com.
-
Email*****@*****.com
-
Telephone+91-****-******
-
Website
-
Social Media**************
-
Registered AddressFlat # 610 6Th Floor H.No.3 – 6 – 237/610, Lingapur La Builders ( Also Known As Amrutha Estate), Himayathnagar, Telangana, India – 500029
-
IndustryPharma, Pharmaceutical Retailers & Distributors
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
Name History of Novelix Pharmaceuticals Limited
Novelix Pharmaceuticals Limited has undergone 2 name changes throughout its history. The company was previously known as Trimurthi Drugs & Pharmaceuticals Limited, and Trimurthi Limited. The current legal name is Novelix Pharmaceuticals Limited, reflecting the company's evolution and rebranding over time.
| Company Name | Status |
|---|---|
| Novelix Pharmaceuticals Limited | Current |
| Trimurthi Drugs & Pharmaceuticals Limited | Previous |
| Trimurthi Limited | Previous |
CIN History of Novelix Pharmaceuticals Limited
Novelix Pharmaceuticals Limited has one previous CIN (Corporate Identification Number): L67120AP1994PLC018956. The current CIN is L67120TG1994PLC018956, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L67120TG1994PLC018956 | Current |
| L67120AP1994PLC018956 | Previous |
Associated Brands with Novelix Pharmaceuticals Limited
Novelix Pharmaceuticals Limited operates one associated brand: Trimurthi drugs and pharmaceuticals. These brands represent Novelix Pharmaceuticals Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Pharmaceutical distribution and retail pharmacy services are provided. | trimurthidrugs.com |
Competitors & Alternatives of Novelix Pharmaceuticals Limited
Brands and companies operating in the same space as Novelix Pharmaceuticals Limited include Entero Healthcare, AmerisourceBergen, WuXi AppTec and 6 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
Entero Healthcare
|
India's leading healthcare products distribution platform | Mumbai, India, India | 2018 |
AmerisourceBergen
|
Pharmaceutical distribution and supply chain services are provided globally. | Chesterbrook, United States, United States | 1985 |
WuXi AppTec
|
Provider of CRO and CDMO services | Shanghai, China, China | 2000 |
Keimed
|
Temperature-sensitive medicines are distributed via cold chain logistics by Keimed. | Hyderabad, India, India | 2000 |
Sandor Medicaids
|
Provider of medical equipment, devices, and drugs distribution services | Hyderabad, India, India | 1995 |
Softgel Healthcare
|
Provider of capsule manufacturing, supply chain, and marketing services for pharmaceutical industry | Chennai, India, India | 2006 |
Mahaveer Medi Sales
|
Serves as a distributor of a wide range of pharmaceutical drugs. | Bengaluru, India, India | 2016 |
Alpha MD
|
Alpha MD is engaged in providing innovative healthcare products and services. | Mumbai, India, India | 2015 |
Hetero
|
Hetero is recognized as a leading global pharmaceutical company based in India. | Hyderabad, India, India | 1993 |
Business Activity of Novelix Pharmaceuticals Limited
Novelix Pharmaceuticals Limited is engaged in principal business activities including trade and financial and insurance service, with detailed activities including wholesale trading, other financial activities. The company has 2 registered principal business activity segments, demonstrating its operational diversity and market reach.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading | ********* |
| K | Financial and insurance Service | K8 | Other financial activities | ********* |
Auditor Details of Novelix Pharmaceuticals Limited
Novelix Pharmaceuticals Limited is audited by CVS. Balachandra Rao & Co. (ICAI peer reviewed, certificate valid till 2026-12-31) for the financial year 2026, as reported in its BSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.
| Name | Financial year | Audit opinion |
|---|---|---|
| CVS. Balachandra Rao & Co. (ICAI peer reviewed, certificate valid till 2026-12-31) | FY 2026 | Declaration of unmodified opinion |
Board of Directors of Novelix Pharmaceuticals Limited
Novelix Pharmaceuticals Limited is currently managed by 9 directors, with 25 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Jivamohan Divakar Valluri | Director | 12 Apr 2025 | 1 Years 2 Months | Current |
|
Gnana Prakash Gattu
Also directs:
Novelix Pharmaceuticals Limited
|
Director | 14 Aug 2025 | 0 Years 10 Months | Current |
|
Nishita Kalantri
Also directs:
Novelix Pharmaceuticals Limited
|
Company Secretary | 01 Apr 2019 | 7 Years 3 Months | Current |
|
Janardhan Das Kabra
Also directs:
Novelix Pharmaceuticals Limited
|
Director | 02 Sep 2024 | 1 Years 10 Months | Current |
|
Venkateshwarlu Pulluru
Also directs:
Novelix Pharmaceuticals Limited, Srinidhi Fine-Chemicals Llp, Nisra Realcon Private Limited and 1 more
|
Whole-Time Director | 02 Sep 2024 | 1 Years 10 Months | Current |
|
Lakshman Samala
Also directs:
Novelix Pharmaceuticals Limited
|
Director | 12 Feb 2025 | 1 Years 4 Months | Current |
Financials of Novelix Pharmaceuticals Limited FY 2026 filings available
Novelix Pharmaceuticals Limited reported revenue of ₹132.31 Cr (up 330.71% YoY) for FY 2026. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | FY 2026 | FY 2025 | FY 2023 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
| Revenue from Operations | ₹132.31 Cr | ₹30.72 Cr | ₹1.4 Cr | ₹98.84 Lakh | ₹1.03 Cr | ₹3.59 Cr |
| Other Income | ₹3.26 Lakh | ₹1.59 Lakh | ₹51.57 Lakh | ₹32.4 Lakh | ₹47.31 Lakh | ₹13.23 Lakh |
| Total Income | ₹132.34 Cr | ₹30.73 Cr | - | ₹1.31 Cr | ₹1.51 Cr | ₹3.72 Cr |
| Cost of Materials Consumed | ₹0 | ₹29.22 Cr | ₹0 | ₹0 | ₹0 | ₹0 |
| Purchases of Stock-in-Trade | ₹140.3 Cr | ₹0 | ₹1.64 Cr | ₹1.19 Cr | ₹73.21 Lakh | ₹2.77 Cr |
| Changes in Inventories | -₹13.59 Cr | ₹35.12 Lakh | -₹28.86 Lakh | -₹16.99 Lakh | ₹2.44 Lakh | ₹3,000 |
| Employee Benefit Expense | ₹71.83 Lakh | ₹6.86 Lakh | ₹31.18 Lakh | ₹30.35 Lakh | ₹28.3 Lakh | ₹32.72 Lakh |
| Finance Costs | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Depreciation & Amortisation | ₹10.11 Lakh | ₹3.8 Lakh | - | ₹8.47 Lakh | ₹7.82 Lakh | ₹12.15 Lakh |
| Other Expenses | ₹1.4 Cr | ₹93.08 Lakh | ₹25.85 Lakh | ₹3.18 Cr | ₹28.12 Lakh | ₹31.39 Lakh |
| Total Expenses | ₹128.93 Cr | ₹30.61 Cr | ₹1.98 Cr | ₹4.58 Cr | ₹1.4 Cr | ₹3.53 Cr |
| Profit Before Exceptional Items & Tax | ₹3.4 Cr | ₹12.33 Lakh | - | -₹3.27 Cr | ₹10.65 Lakh | ₹19.08 Lakh |
| Exceptional Items | ₹0 | ₹0 | - | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹3.4 Cr | ₹12.33 Lakh | -₹5.85 Lakh | -₹3.27 Cr | ₹10.65 Lakh | ₹19.08 Lakh |
| Total Tax Expense | ₹84.77 Lakh | ₹3.88 Lakh | ₹14,900 | -₹22,000 | ₹1.17 Lakh | -₹5.91 Lakh |
| Net Profit | ₹2.56 Cr | ₹8.45 Lakh | -₹6 Lakh | -₹3.27 Cr | ₹9.48 Lakh | ₹24.99 Lakh |
| Other Comprehensive Income | ₹0 | ₹0 | - | ₹11,000 | ₹6.05 Lakh | -₹6.2 Lakh |
| Total Comprehensive Income | ₹2.56 Cr | ₹8.45 Lakh | - | -₹3.27 Cr | ₹15.53 Lakh | ₹18.79 Lakh |
| EBITDA (computed) | ₹3.51 Cr | ₹16.13 Lakh | - | -₹3.19 Cr | ₹18.47 Lakh | ₹31.23 Lakh |
| Basic EPS | ₹1.21 | ₹0.08 | - | ₹-4.04 | ₹0.12 | ₹0.31 |
| Diluted EPS | ₹1.75 | ₹0.09 | - | ₹-4.04 | ₹0.12 | ₹0.31 |
| Metrics | FY 2026 | FY 2025 | FY 2023 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
| Total Assets | ₹92.42 Cr | ₹27.21 Cr | ₹7.26 Cr | ₹8.77 Cr | ₹12.04 Cr | ₹12.13 Cr |
| Non-current Assets | ₹3.51 Cr | ₹27.35 Lakh | ₹3.01 Cr | ₹4.07 Cr | ₹4.04 Cr | ₹3.3 Cr |
| Current Assets | ₹88.91 Cr | ₹26.93 Cr | ₹4.24 Cr | ₹4.7 Cr | ₹8 Cr | ₹8.83 Cr |
| Property, Plant & Equipment | ₹1.52 Cr | ₹18.57 Lakh | - | ₹22.43 Lakh | ₹30.82 Lakh | ₹36.86 Lakh |
| Inventories | ₹14.43 Cr | ₹84.32 Lakh | ₹82.06 Lakh | ₹24.82 Lakh | ₹7.83 Lakh | ₹10.27 Lakh |
| Trade Receivables | ₹58.96 Cr | ₹18.14 Cr | - | ₹8.5 Lakh | ₹2.28 Cr | ₹2.14 Cr |
| Cash & Equivalents | ₹2.96 Cr | ₹67.86 Lakh | ₹2.77 Cr | ₹1.74 Cr | ₹95.23 Lakh | ₹16.03 Lakh |
| Equity (Net Worth) | ₹46.49 Cr | ₹17.54 Cr | - | ₹8.8 Cr | ₹12.07 Cr | ₹12.01 Cr |
| Equity Share Capital | ₹21.09 Cr | ₹9.95 Cr | - | ₹8.1 Cr | ₹8.1 Cr | ₹8.1 Cr |
| Borrowings (Non-current) | ₹4.32 Cr | ₹0 | - | ₹0 | ₹0 | ₹0 |
| Borrowings (Current) | ₹0 | ₹0 | - | ₹0 | ₹0 | ₹0 |
| Total Debt (computed) | ₹4.32 Cr | ₹0 | - | ₹0 | ₹0 | ₹0 |
| Current Liabilities | ₹41.61 Cr | ₹9.67 Cr | ₹6.17 Lakh | ₹2.41 Lakh | ₹2.73 Lakh | ₹18.46 Lakh |
| Total Liabilities | ₹45.93 Cr | ₹9.67 Cr | - | -₹3.65 Lakh | -₹3.12 Lakh | ₹12.08 Lakh |
| Metrics | FY 2026 | FY 2025 | FY 2023 |
|---|---|---|---|
| Operating Cash Flow | -₹22.39 Cr | -₹13.68 Cr | ₹9.47 Lakh |
| Investing Cash Flow | -₹1.72 Cr | ₹2.93 Cr | ₹7.51 Lakh |
| Financing Cash Flow | ₹26.39 Cr | ₹11.32 Cr | ₹0 |
| Capital Expenditure | ₹3.26 Cr | ₹0 | - |
| Free Cash Flow (computed) | -₹25.65 Cr | -₹13.68 Cr | - |
| Dividends Paid | ₹0 | ₹0 | ₹0 |
| Net Change in Cash | ₹2.28 Cr | ₹56.08 Lakh | ₹16.98 Lakh |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 |
|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹25.19 Cr | ₹48.4 Cr | ₹36.36 Cr | ₹22.35 Cr | ₹20.86 Cr | ₹5.3 Cr | ₹3.96 Cr |
| Other Income | ₹0 | ₹2,000 | ₹3.25 Lakh | ₹0 | ₹0 | ₹10,800 | -₹8.29 Lakh |
| Total Income | ₹25.19 Cr | ₹48.4 Cr | ₹36.39 Cr | ₹22.35 Cr | ₹20.86 Cr | ₹5.3 Cr | ₹3.87 Cr |
| Cost of Materials Consumed | ₹0 | ₹0 | ₹0 | ₹0 | ₹20.22 Cr | ₹0 | ₹0 |
| Purchases of Stock-in-Trade | ₹32.84 Cr | ₹48.28 Cr | ₹36.68 Cr | ₹22.5 Cr | ₹0 | ₹5.61 Cr | ₹3.03 Cr |
| Changes in Inventories | -₹9.94 Cr | -₹1.43 Cr | -₹1.5 Cr | -₹71.64 Lakh | ₹6.77 Lakh | -₹58.95 Lakh | ₹45.33 Lakh |
| Employee Benefit Expense | ₹23.9 Lakh | ₹17.3 Lakh | ₹14.18 Lakh | ₹16.46 Lakh | ₹73,000 | ₹78,000 | ₹1.71 Lakh |
| Finance Costs | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Depreciation & Amortisation | ₹4.61 Lakh | ₹3.03 Lakh | ₹1.38 Lakh | ₹1.1 Lakh | ₹2.34 Lakh | ₹48,700 | ₹48,000 |
| Other Expenses | ₹77.65 Lakh | ₹6.73 Lakh | ₹32.89 Lakh | ₹22.76 Lakh | ₹33.59 Lakh | ₹13.84 Lakh | ₹23.85 Lakh |
| Total Expenses | ₹23.96 Cr | ₹47.12 Cr | ₹35.67 Cr | ₹22.18 Cr | ₹20.65 Cr | ₹5.17 Cr | ₹3.74 Cr |
| Profit Before Exceptional Items & Tax | ₹1.23 Cr | ₹1.28 Cr | ₹71.88 Lakh | ₹16.94 Lakh | ₹21.06 Lakh | ₹12.8 Lakh | ₹13.07 Lakh |
| Exceptional Items | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹1.23 Cr | ₹1.28 Cr | ₹71.88 Lakh | ₹16.94 Lakh | ₹21.06 Lakh | ₹12.8 Lakh | ₹13.07 Lakh |
| Total Tax Expense | ₹32.1 Lakh | ₹27.87 Lakh | ₹18.57 Lakh | ₹6.24 Lakh | ₹2.81 Lakh | -₹1.99 Lakh | ₹12,000 |
| Net Profit | ₹91.19 Lakh | ₹1 Cr | ₹53.31 Lakh | ₹10.7 Lakh | ₹18.25 Lakh | ₹14.79 Lakh | ₹12.95 Lakh |
| Other Comprehensive Income | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Total Comprehensive Income | ₹91.19 Lakh | ₹1 Cr | ₹53.31 Lakh | ₹10.7 Lakh | ₹18.25 Lakh | ₹14.79 Lakh | ₹12.95 Lakh |
| EBITDA (computed) | ₹1.28 Cr | ₹1.31 Cr | ₹73.26 Lakh | ₹18.04 Lakh | ₹23.4 Lakh | ₹13.29 Lakh | ₹13.55 Lakh |
| Basic EPS | ₹0.43 | ₹0.58 | ₹0.37 | ₹0.09 | ₹0.18 | ₹0.15 | ₹0.00 |
| Diluted EPS | ₹0.32 | ₹0.85 | ₹0.49 | ₹0.11 | ₹0.20 | ₹0.16 | ₹0.00 |
| Segment · Q4 FY26 (latest quarter) | Revenue | Result (PBIT) | Assets | Liabilities |
|---|---|---|---|---|
| Pharma Business | ₹25.19 Cr | ₹1.23 Cr | ₹92.38 Cr | ₹92.42 Cr |
| Investment in Shares | ₹0 | ₹0 | ₹0 | ₹0 |
| Trading in shares | ₹0 | ₹0 | ₹0 | ₹0 |
| Foods | ₹0 | ₹0 | ₹0 | ₹0 |
| Finance | ₹0 | ₹0 | ₹0 | ₹0 |
| Segment · FY 2026 (annual) | Revenue | Result (PBIT) | Assets | Liabilities |
|---|---|---|---|---|
| Pharma Business | ₹132.31 Cr | ₹1.23 Cr | - | - |
| Investment in Shares | ₹0 | ₹0 | - | - |
| Trading in shares | ₹0 | ₹0 | - | - |
| Foods | ₹0 | ₹0 | - | - |
| Finance | ₹0 | ₹0 | - | - |
| Metrics | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|
| Revenue from Operations | ₹9.24 Cr | ₹10.24 Cr | ₹10.46 Cr |
| Other Income | ₹34.41 Lakh | ₹60.11 Lakh | ₹37.73 Lakh |
| Total Income | ₹9.59 Cr | ₹10.85 Cr | ₹10.84 Cr |
| Cost of Materials Consumed | ₹2.02 Cr | ₹2.12 Cr | ₹1.54 Cr |
| Purchases of Stock-in-Trade | ₹5.01 Cr | ₹5.52 Cr | ₹5.94 Cr |
| Changes in Inventories | -₹2.97 Lakh | -₹9.45 Lakh | ₹1.95 Lakh |
| Employee Benefit Expense | ₹98.68 Lakh | ₹96.49 Lakh | ₹98.62 Lakh |
| Finance Costs | ₹6.34 Lakh | ₹11.45 Lakh | ₹12.97 Lakh |
| Depreciation & Amortisation | ₹20.85 Lakh | ₹19.14 Lakh | ₹21.25 Lakh |
| Other Expenses | ₹5.05 Cr | ₹2.24 Cr | ₹2.13 Cr |
| Total Expenses | ₹13.31 Cr | ₹11.06 Cr | ₹10.96 Cr |
| Profit Before Exceptional Items & Tax | -₹3.73 Cr | -₹21.49 Lakh | -₹12.4 Lakh |
| Exceptional Items | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | -₹3.73 Cr | -₹21.49 Lakh | -₹12.4 Lakh |
| Total Tax Expense | ₹1.38 Lakh | ₹4.42 Lakh | ₹2.39 Lakh |
| Net Profit | -₹3.76 Cr | -₹25.91 Lakh | -₹14.79 Lakh |
| attributable to Owners | - | ₹0 | ₹0 |
| attributable to NCI | - | ₹0 | ₹0 |
| Other Comprehensive Income | ₹11,000 | -₹3.43 Lakh | -₹43,000 |
| Total Comprehensive Income | -₹3.76 Cr | -₹29.34 Lakh | -₹15.22 Lakh |
| EBITDA (computed) | -₹3.45 Cr | ₹9.1 Lakh | ₹21.82 Lakh |
| Basic EPS | ₹-4.62 | ₹-0.35 | ₹-0.03 |
| Diluted EPS | ₹-4.62 | ₹-0.35 | ₹-0.03 |
| Metrics | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|
| Total Assets | ₹9.57 Cr | ₹13.72 Cr | ₹13.34 Cr |
| Non-current Assets | ₹2.24 Cr | ₹2.33 Cr | ₹2.62 Cr |
| Current Assets | ₹7.33 Cr | ₹11.39 Cr | ₹10.72 Cr |
| Property, Plant & Equipment | ₹1.62 Cr | ₹1.78 Cr | ₹1.89 Cr |
| Inventories | ₹92.66 Lakh | ₹90.68 Lakh | ₹79.4 Lakh |
| Trade Receivables | ₹1.38 Cr | ₹3.51 Cr | ₹3.29 Cr |
| Cash & Equivalents | ₹2.08 Cr | ₹1.12 Cr | ₹19.93 Lakh |
| Equity (Net Worth) | ₹7.37 Cr | ₹11.13 Cr | ₹11.42 Cr |
| Equity Share Capital | ₹8.1 Cr | ₹8.1 Cr | ₹8.1 Cr |
| Borrowings (Non-current) | ₹0 | ₹76.72 Lakh | ₹93.07 Lakh |
| Borrowings (Current) | ₹0 | ₹0 | ₹0 |
| Total Debt (computed) | ₹0 | ₹76.72 Lakh | ₹93.07 Lakh |
| Current Liabilities | ₹2.18 Cr | ₹1.81 Cr | ₹98.62 Lakh |
| Total Liabilities | ₹2.21 Cr | ₹2.59 Cr | ₹1.92 Cr |
| Metrics |
|---|
| Segment · FY 2021 (annual) | Revenue | Result (PBIT) | Assets | Liabilities |
|---|---|---|---|---|
| Pharma Business | ₹4.51 Cr | -₹5.75 Lakh | - | - |
| Financial Services | ₹33.38 Lakh | ₹27.04 Lakh | - | - |
| Investments | ₹96,000 | ₹96,000 | - | - |
| Foods | ₹3.75 Cr | -₹35.44 Lakh | - | - |
| Trading in Shares | ₹98.84 Lakh | -₹3.59 Cr | - | - |
Shareholding Pattern of Novelix Pharmaceuticals Limited
As per the shareholding pattern filed with BSE for the quarter ended Mar 2026, promoters hold 49.43%, retail and other public shareholders hold 50.57% of Novelix Pharmaceuticals Limited. The company had 2,975 shareholders on record.
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Promoters | 49.43% | 51.98% | 53.33% | 52.75% | 66.56% | 66.56% |
| Public | 50.57% | 48.02% | 46.67% | 47.25% | 33.44% | 33.44% |
| Mar 2026 | Mar 2025 | Mar 2024 | |
|---|---|---|---|
| Promoters | 49.43% | 66.56% | 66.92% |
| Public | 50.57% | 33.44% | 33.08% |
| Promoter change (YoY, %pts) | -17.13 | -0.36 | - |
Group Structure of Novelix Pharmaceuticals Limited
Novelix Pharmaceuticals Limited has 1 subsidiary company. This group structure data is as of FY 2022. The corporate group structure reflects Novelix Pharmaceuticals Limited's business expansion strategy and organizational complexity.
| Company Name | CIN | Shares Held |
|---|---|---|
| Trimurthi Pharmaceuticals (India) Private Limited | U24232TG2012PTC080276 | - |
Showing major subsidiaries. Total: 1.
Charges & Borrowings of Novelix Pharmaceuticals Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 07 Nov 2025 | Canara Bank | ₹85 Lakh | Open |
Total charge records: 1 View all charges
Employees and EPFO Compliance at Novelix Pharmaceuticals Limited
View historical data on people associated with Novelix Pharmaceuticals Limited, including employment history and EPFO contributions.
Employee Count & EPFO Data of Novelix Pharmaceuticals Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Novelix Pharmaceuticals Limited
GSTIN & GST Filing Data of Novelix Pharmaceuticals Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Novelix Pharmaceuticals Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Novelix Pharmaceuticals Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Novelix Pharmaceuticals Limited
MSME Payment Delays by Novelix Pharmaceuticals Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Novelix Pharmaceuticals Limited
Subsidiaries & Group Companies of Novelix Pharmaceuticals Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Novelix Pharmaceuticals Limited with ownership details.
MCA Filings & Documents of Novelix Pharmaceuticals Limited
MCA Filings & Documents of Novelix Pharmaceuticals Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Novelix Pharmaceuticals Limited
Frequently Asked Questions about Novelix Pharmaceuticals Limited
Novelix Pharmaceuticals Limited is an active public limited company in the pharma sector based in Himayathnagar, Telangana, India. It was incorporated on 13 December 1994 (32+ years old) and is registered under CIN L67120TG1994PLC018956. Listed on BSE: 536565.
Novelix Pharmaceuticals Limited reported revenue of ₹4.53 Cr for FY 2024 (up 136.00% YoY).
The current directors of Novelix Pharmaceuticals Limited are:
The primary industry of Novelix Pharmaceuticals Limited is pharma. The company specifically operates in pharmaceutical retailers and distributors. The company is currently active in this sector.
Yes. Novelix Pharmaceuticals Limited is listed on BSE with code 536565.
Novelix Pharmaceuticals Limited can be reached at the registered office: Flat # 610 6Th Floor H.No.3 – 6 – 237610, Lingapur La Builders Also Known As Amrutha Estate, Himayathnagar, Telangana, India – 500029, or through the website trimurthidrugs.com.